Sandoz to set up standalone biosimilars unit as it eyes upcoming 'golden decade' of patent losses

10th March 2026 Uncategorised 0

Sandoz is committing even further to its biosimilar business with plans to launch a dedicated unit that will operate separately from the company’s remaining small molecule generics division.

More: Sandoz to set up standalone biosimilars unit as it eyes upcoming 'golden decade' of patent losses
Source: fierce